2026-05-14T10:08:51-05:00 2025-12-31 871353108 EISNER ADVISORY GROUP LLC 130 NORTH 18TH STREET SUITE 3000 PHILADELPHIA PA 191032757 990 2025-01-01 460886344 TRANSCELERATE BIOPHARMA INC TRAN 4845391230 300 CONSHOHOCKEN STATE ROAD 420 WEST CONSHOHOCKEN PA 19428 JANICE CHANG CEO 4845391230 2026-05-06 1 HELEN M MARTIN P01330899 2158818800 2025 2025-03-06 01:10:19Z JANICE CHANG 300 CONSHOHOCKEN STATE ROAD 420 WEST CONSHOHOCKEN PA 19428 34242546 0 X WWW.TRANSCELERATEBIOPHARMAINC.COM X 2012 DE IMPROVE THE HEALTH OF PEOPLE IN THE WORLD BY ENHANCING THE R&D OF INNOVATIVE THERAPIES. 21 20 35 28 0 0 0 0 37402000 33003000 1193799 1239546 0 0 38595799 34242546 0 0 0 0 9759153 11246091 0 0 0 21980786 21786213 31739939 33032304 6855860 1210242 55325009 55072425 36830722 35380185 18494287 19692240 X THE ORGANIZATION'S MISSION IS TO COLLABORATE ACROSS THE GLOBAL BIOPHARMACEUTICAL R&D COMMUNITY TO IDENTIFY, DESIGN AND FACILITATE IMPLEMENTATION OF SOLUTIONS DESIGNED TO DRIVE THE EFFICIENT, EFFECTIVE AND HIGH QUALITY DELIVERY OF NEW MEDICINES. 0 0 22040051 33003000 IN 2025, TRANSCELERATE DELIVERED PRACTICAL SOLUTIONS TO SIMPLIFY TRIAL DESIGN AND EXECUTION, STRENGTHEN QUALITY, AND REDUCE BURDEN ACROSS THE R&D ECOSYSTEM. THE APPROACH COMBINED RAPID IMPROVEMENTS FOR IMMEDIATE IMPLEMENTATION WITH LONG-TERM SOLUTIONS TO HELP PROMISING THERAPIES REACH PATIENTS MORE QUICKLY AND SAFELY.THE ORGANIZATION LED 12 ACTIVE INITIATIVES IN 2025 AND LAUNCHED MORE THAN 60 TOOLS AND SOLUTIONS ACROSS THREE AREAS OF FOCUS:- TRANSFORMING CONNECTIVITY: REDEFINING HOW RESEARCH AND CARE INTERACT- INFORMATION SHARING AND REUSE: LEVERAGING EXISTING DATA FOR FASTER DEVELOPMENT- INNOVATIVE TRIAL DESIGN: PUTTING PATIENTS AT THE HEART OF CLINICAL TRIALS.HIGHLIGHTS OF 2025 PROGRESS:- DIGITAL DATA FLOW (DDF): SPONSORS CONTINUED TO ADOPT DDF WHILE GROWING INTEREST FROM SOLUTION PROVIDERS SHOWED THAT DIGITAL PROTOCOL INNOVATION IS MOVING FROM EARLY PILOT TO EVERYDAY PRACTICE.- ICH E6(R3) SUPPORT: FIFTEEN PRACTICAL TOOLS GAVE THE INDUSTRY WAYS TO ADAPT TO MUCH-ANTICIPATED NEW GUIDANCE ON GOOD CLINICAL PRACTICE EARNING WIDE MEDIA COVERAGE ALONG THE WAY.- CLINICAL DATA SHARING: USAGE OF TRANSCELERATE'S DATACELERATE PLATFORM MORE THAN DOUBLED, DEMONSTRATING THE GROWING IMPACT OF DATA REUSE TO REDUCE BURDEN AND IMPROVE TRIAL DESIGN.- PATIENT SAFETY REPORTING: A MANUSCRIPT IN A PROMINENT JOURNAL AND DIALOGUE WITH MULTIPLE HEALTH AUTHORITIES MARKED CRUCIAL FIRST STEPS TOWARD MODERNIZING INDIVIDUAL CASE SAFETY REPORTING. - EMBEDDED PRAGMATIC TRIALS: TRANSCELERATE PUBLISHED A NEW RESOURCE GUIDE AND IN COLLABORATION WITH THE FDA RELEASED A PUBLIC SUMMARY OF A JOINT EXERCISE TO IDENTIFY ACTIONABLE OPPORTUNITIES TO SCALE THE USE OF PRAGMATIC ELEMENTS.TRANSCELERATE HEALTH AUTHORITY DIALOGUE EXPANDED ACROSS FOUR CONTINENTS WITH CONTINUED FOCUS ON PRODUCTIVE COLLABORATION. THE ORGANIZATION ALSO PARTNERED WITH A VARIETY OF OUTSIDE ORGANIZATIONS, INCLUDING WITH THE TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT (CSDD) TO PUBLISH A BENCHMARKING STUDY ON PROTOCOL COMPLEXITY.- TRANSCELERATE GLOBAL REACH AND PRESENCE EXPANDED IN 2025. HIGHLIGHTS INCLUDED HOSTING 8 PUBLIC WEBINARS REACHING 7,000+ PROFESSIONALS, COVERAGE IN 50+ PUBLICATIONS, AND PRESENTATIONS AT MORE THAN 20 CONFERENCES ACROSS NORTH AMERICA, EUROPE, ASIA, AND SOUTH AMERICA.THE ORGANIZATION'S WORK IN 2025 WAS AND WILL CONTINUE TO BE ORIENTED AROUND A VISION OF SEAMLESS CONVERGENCE OF RESEARCH AND CARE, SO THAT TRIAL PARTICIPATION BECOMES A NATURAL PART OF HEALTHCARE PROCESSES. 22040051 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 21 0 1 35 1 0 0 0 0 0 0 0 0 X 21 20 0 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 0 1 1 0 X ANTHONY GARGES HEAD OF FINANCE AND ADMINISTRATION 4845391230 300 CONSHOHOCKEN STATE ROAD STE 420 WEST CONSHOHOCKEN PA 19428 JANICE CHANG CEO 40.00 X X 1174019 0 53270 ELIAV BARR BOARD MEMBER 0.50 X 0 0 0 KAMRAN ANSARI BOARD MEMBER 0.50 X 0 0 0 LIONEL BASCLES BOARD MEMBER 0.50 X 0 0 0 DIETMAR BERGER BOARD MEMBER (EFF 3/2025) 0.50 X 0 0 0 PHILLIPPA BROWN BOARD MEMBER (EFF 4/2025) 0.50 X 0 0 0 SERBAN GHIORGHIU BOARD MEMBER (EFF 8/2025) 0.50 X 0 0 0 RUCHIRA GLASER BOARD MEMBER 0.50 X 0 0 0 LYKKE HINSCH GYLVIN BOARD MEMBER 0.50 X 0 0 0 ELIZABETH VAN SANT HOFFMAN BOARD MEMBER (EFF 4/2025) 0.50 X 0 0 0 NARIMON HONARPOUR BOARD MEMBER 0.50 X 0 0 0 CHRISTOPH KOENEN BOARD MEMBER 0.50 X 0 0 0 MARIA KOUTSOPOULOU BOARD MEMBER 0.50 X 0 0 0 BARI KOWAL BOARD MEMBER 0.50 X 0 0 0 FABIO LIEVANO BOARD MEMBER 0.50 X 0 0 0 FIONA DU MONCEAU BOARD MEMBER (EFF 3/2025) 0.50 X 0 0 0 MARIANNE OLHOLM BOARD MEMBER (EFF 12/2025) 0.50 X 0 0 0 MICHELLE ROHRER BOARD MEMBER 0.50 X 0 0 0 MOKASH SHARMA BOARD MEMBER 0.50 X 0 0 0 TADAAKI TANIGUCHI BOARD MEMBER 0.50 X 0 0 0 TAKEKI UEHARA BOARD MEMBER (EFF 12/2025) 0.50 X 0 0 0 CHRIS CORSICO BOARD MEMBER (THRU 3/2025) 0.50 X 0 0 0 CRISTIAN MASSACESI BOARD MEMBER (THRU 8/2025) 0.50 X 0 0 0 ROBERT METCALF BOARD MEMBER (THRU 3/2025) 0.50 X 0 0 0 MERDAD PARSEY BOARD MEMBER (THRU 3/2025) 0.50 X 0 0 0 TOM SENDEROVITZ BOARD MEMBER (THRU 10/2025) 0.50 X 0 0 0 BADHRI SRINIVASAN BOARD MEMBER (THRU 1/2025) 0.50 X 0 0 0 TAKUKO YAMADA-SAWADA BOARD MEMBER (THRU 12/2025) 0.50 X 0 0 0 IRIS LOEW-FRIEDRICH BOARD MEMBER (THRU 3/2025) 0.50 X 0 0 0 ALLISON CUFF SHIMOOKA COO 40.00 X 657690 0 59759 JENNIFER SHELLER TREASURER (EFF 8/2025) 0.50 X 0 0 0 RAJA MANGIPUDY CORPORATE SECRETARY (EFF 4/2025) 0.50 X 0 0 0 ANDREW LEE TREASURER (THRU 6/2025) 0.50 X 0 0 0 JENNIFER BURGESS VP, GLOBAL COMM & ENGAG (THRU 7/2025) 40.00 X 486057 0 51172 CARA RINALDI VP, PORTFOLIO MANAGEMENT 40.00 X 448212 0 59095 ANTHONY GARGES HEAD OF FINANCE & ADMINISTRATION 40.00 X 435545 0 58512 JENEEN DONADEO EXEC. PORTFOLIO DIRECTOR 40.00 X 411601 0 47045 ROBERT DICICCIO VP, PORTFOLIO MANAGEMENT 40.00 X 435340 0 55553 4048464 0 384406 28 0 1 0 PA CONSULTING GROUP INC 10 BRESSENDEN PLACE LONDON UK CONSULTING SERVICES 6966076 KILPATRICK TOWNSEND 601 14TH STREET NW SUITE 900 WASHINGTON DC 20005 LEGAL SERVICES 3025405 ACCENTURE LLP 161 N CLARK STREET CHICAGO IL 60601 CONSULTING & IT SERVICES 2931600 VYNAMIC LLC 1600 ARCH STREET PHILADELPHIA PA 19103 CONSULTING SERVICES 1606532 ARTEMIS FACTOR LLC 314 CARLYLE ROAD WEST CHESTER PA 19382 CONSULTING SERVICES 1392285 21 MEMBERSHIP DUES 541900 33003000 33003000 33003000 1239546 1239546 34242546 33003000 0 1239546 X 1940738 1940738 7729478 4365622 3363856 300338 203902 96436 812560 420882 391678 462977 307105 155872 3005795 1739172 1266623 26458 26458 14388053 12990192 1397861 40337 17360 22977 59848 59848 2599472 1873710 725762 364676 364676 580873 121043 459830 359588 1063 358525 262011 262011 EXCESS COMPENSATION TAX 36861 36861 RECRUITING 35896 35896 ADMINISTRATIVE FEES 18454 18454 BOOKS, SUBSCRIPTIONS, R 6916 6916 975 975 33032304 22040051 10992253 0 2528531 2528020 21990173 25203908 30577703 27074905 201619 238609 26983 26983 55325009 55072425 3827722 3778185 33003000 31602000 36830722 35380185 X 18494287 19692240 18494287 19692240 55325009 55072425 1210242 -12289 0 X 0 0 0 0 1 0 X X 1 0 0 JANICE CHANG CEO 810141 0 363878 0 0 0 21000 0 32270 0 1227289 0 0 0 ALLISON CUFF SHIMOOKA COO 456067 0 201623 0 0 0 21000 0 38759 0 717449 0 0 0 JENNIFER BURGESS VP, GLOBAL COMM & ENGAG (THRU 7/2025 221441 0 105579 0 159037 0 14155 0 37017 0 537229 0 0 0 CARA RINALDI VP, PORTFOLIO MANAGEMENT 337322 0 110890 0 0 0 0 0 59095 0 507307 0 0 0 ANTHONY GARGES HEAD OF FINANCE & ADMINISTRATION 351179 0 84366 0 0 0 21000 0 37512 0 494057 0 0 0 ROBERT DICICCIO VP, PORTFOLIO MANAGEMENT 328123 0 107217 0 0 0 2042 0 53511 0 490893 0 0 0 JENEEN DONADEO EXEC. PORTFOLIO DIRECTOR 317681 0 93920 0 0 0 21000 0 26045 0 458646 0 0 0 PART I, LINE 3 THE ORGANIZATION'S EXECUTIVE COMPENSATION COMMITTEE, CONSISTING OF INDEPENDENT DIRECTORS, ANNUALLY REVIEWS AND APPROVES THE CEO'S COMPENSATION PACKAGE. THE CEO APPROVES THE COMPENSATION FOR THE CHIEF OPERATING OFFICER, AND ALL OTHER KEY EMPLOYEES. PART I, LINE 4A VICE PRESIDENT, GLOBAL COMMUNICATIONS & ENGAGEMENT RECEIVED A SEVERANCE THROUGH MARCH 2026 OF SALARY, COBRA AND AN $8,000 REIMBURSEMENT FOR TRANSITION COACHING SERVICES. FORM 990, PART I, LINE 6, TOTAL NUMBER OF VOLUNTEERS: THE TOTAL NUMBER OF VOLUNTEERS OF 21, ENCOMPASSES ALL ACTIVE BOARD MEMBER THROUGHOUT THE CALENDAR YEAR. FORM 990, PART VI, SECTION A, LINE 6 THE MEMBERS OF THE CORPORATION CONSIST OF SUCH FIRMS AND CORPORATIONS THAT ARE APPROVED FOR MEMBERSHIP FROM TIME TO TIME BY THE BOARD OF DIRECTORS OR ITS DESIGNEES IN ACCORDANCE WITH THE POLICIES AND PROCEDURES OF THE CORPORATION. THE CORPORATION HAS THE FOLLOWING CATEGORIES OF MEMBERS: A. TIER I MEMBERS - TO BE ELIGIBLE FOR TIER I MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT IN EXCESS OF AN AMOUNT EQUAL TO $3.3 BILLION AS OF JANUARY 1, 2024, WHICH AMOUNT SHALL THEREAFTER BE ADJUSTED FOR INFLATION IN ACCORDANCE WITH THE U.S. CPI INDEX (THE "TIER I THRESHOLD"). THE ADJUSTED TIER I THRESHOLD SHALL BE ANNOUNCED TO THE MEMBERS PERIODICALLY BY THE FINANCE COMMITTEE OR THE BOARD OF DIRECTORS. ELIGIBILITY FOR TIER I MEMBERSHIP IS ESTABLISHED BASED UPON THE AVERAGE OF A COMPANY'S PUBLICALLY AVAILABLE RESEARCH AND DEVELOPMENT EXPENDITURES OVER THE PRECEDING THREE (3) YEAR PERIOD. THE INITIAL TIER I MEMBERS ARE FURTHER DEFINED AS THE "CHARTER MEMBERS." B. TIER II MEMBERS - TO BE ELIGIBLE FOR TIER II MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN THE TIER I THRESHOLD BUT MORE THAN AN AMOUNT EQUAL TO $134 MILLION AS OF JANUARY 1, 2024, WHICH AMOUNT SHALL THEREAFTER BE ADJUSTED FOR INFLATION IN ACCORDANCE WITH THE U.S. CPI INDEX (THE "TIER II THRESHOLD"). THE ADJUSTED TIER II THRESHOLD SHALL BE ANNOUNCED TO THE MEMBERS PERIODICALLY BY THE FINANCE COMMITTEE OR THE BOARD OF DIRECTORS.. ELIGIBILITY FOR TIER II MEMBERSHIP WILL BE ESTABLISHED BASED UPON THE AVERAGE OF A COMPANY'S PUBLICALLY AVAILABLE RESEARCH AND DEVELOPMENT EXPENDITURES OVER THE PRECEDING THREE (3) YEAR PERIOD. C. ASSOCIATE MEMBERS - TO BE ELIGIBLE FOR ASSOCIATE MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN THE TIER II THRESHOLD. FORM 990, PART VI, SECTION A, LINE 7A THE BOARD OF DIRECTORS SHALL BE COMPRISED OF UP TO TWENTY-FOUR (24) DIRECTORS; PROVIDED THAT: (I) TEN (10) SEATS ARE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE CHARTER MEMBERS; (II) UP TO SEVEN (7) ADDITIONAL SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER I MEMBERS WHO ARE NOT CHARTER MEMBERS; (III) UP TO SIX (6) SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER II MEMBERS; AND (IV) ONE (1) SEAT SHALL BE FILLED BY THE CHIEF EXECUTIVE OFFICER OF THE CORPORATION. THE CORPORATION'S BYLAWS STATE THAT DIRECTORS SHALL BE ELECTED OR APPOINTED, AS APPLICABLE, ANNUALLY AT THE ANNUAL MEETING OF MEMBERS AND SHALL SERVE UNTIL THE FOLLOWING ANNUAL MEETING OF MEMBERS AND UNTIL THEIR SUCCESSORS ARE ELECTED OR APPOINTED, AS APPLICABLE, AND QUALIFIED. EACH CHARTER MEMBER SHALL HAVE THE RIGHT TO APPOINT A REPRESENTATIVE OF THE CHARTER MEMBER TO SERVE AS A CHARTER MEMBER DIRECTOR. TIER I AT-LARGE DIRECTORS SHALL BE ELECTED BY A PLURALITY VOTE OF THE TIER I MEMBERS, WHICH INCLUDE THE CHARTER MEMBERS. TIER II DIRECTORS SHALL BE ELECTED BY A PLURALITY VOTE OF THE TIER II MEMBERS. THE CEO DIRECTOR SHALL SERVE EX-OFFICIO, FOR SO LONG AS HE OR SHE SHALL HOLD THE OFFICE OF CHIEF EXECUTIVE OFFICER. EACH TIER I MEMBER SHALL BE ENTITLED TO THREE (3) VOTES AT EVERY MEETING OF MEMBERS ON MATTERS WHICH TIER I MEMBERS ARE ENTITLED TO VOTE. EACH TIER II MEMBER SHALL BE ENTITLED TO ONE (1) VOTE AT EVERY MEETING OF MEMBERS ON MATTERS WHICH TIER II MEMBERS ARE ENTITLED TO VOTE. ASSOCIATE MEMBERS SHALL BE ENTITLED TO NOTICE OF AND TO ATTEND MEETINGS OF THE MEMBERS BUT SHALL NOT BE ENTITLED TO VOTE AT SUCH MEETINGS. NOTWITHSTANDING THE ABOVE, IN ORDER TO BE ELIGIBLE TO VOTE, A MEMBER MUST BE IN GOOD STANDING AND ITS DUES AND ASSESSMENTS PAID IN FULL. FORM 990, PART VI, SECTION B, LINE 11B THE FINANCE COMMITTEE AND MANAGEMENT REVIEW AND APPROVE THE FORM 990. THE FORM IS THEN DISTRIBUTED TO ALL MEMBERS OF THE BOARD FOR THEIR REVIEW BEFORE FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C EACH DIRECTOR AND OFFICER OF THE CORPORATION IS REQUIRED TO ANNUALLY ACKNOWLEDGE THE CONFLICT OF INTEREST POLICY, AFFIRMING THAT SUCH PERSON HAS RECEIVED, READ AND UNDERSTANDS, AND AGREED TO COMPLY WITH THE CONFLICT OF INTEREST POLICY. FORM 990, PART VI, SECTION B, LINE 15 THE ORGANIZATION'S EXECUTIVE COMPENSATION COMMITTEE, CONSISTING OF INDEPENDENT DIRECTORS, ANNUALLY REVIEWS AND APPROVES THE CEO'S COMPENSATION PACKAGE. THE CEO APPROVES THE COMPENSATION FOR THE CHIEF OPERATING OFFICER, AND ALL OTHER KEY EMPLOYEES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS, FINANCIAL STATEMENTS, CONFLICT OF INTEREST POLICY AND OTHER CORPORATE POLICIES ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G PROJECT MANAGEMENT FEES: PROGRAM SERVICE EXPENSES 10,226,712. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 10,226,712. EXTERNAL CONTRACTOR SUPPORT: PROGRAM SERVICE EXPENSES 2,146,789. MANAGEMENT AND GENERAL EXPENSES 152,626. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,299,415. COMMUNICATIONS FEES: PROGRAM SERVICE EXPENSES 616,691. MANAGEMENT AND GENERAL EXPENSES 1,243,573. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,860,264. PAYROLL EXPENSES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 1,662. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,662. BIOCELERATE LLC 300 CONSHOHOCKEN STATE ROAD STE 420 WEST CONSHOHOCKEN PA 19428 475492971 TO IMPROVE EFFICIENCIES IN PRECLINICAL RESEARCH. DE 1037224 1740865 TRANSCELERATE BIOPHARMA INC